Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly ...
News Medical on MSN2d
Affordability and supply remain critical to the success of long-lasting HIV drugAffordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...
Cisgender gay and bisexual men, transgender women, and transgender men remain at higher risk for HIV acquisition.
The drug has been approved in Europe and the US as a treatment for HIV/AIDS but does not yet have regulatory approval anywhere in the world as an HIV prevention drug. Once approved, producing enough ...
GlobalData on MSN2d
Gilead and MSD to advance once-weekly HIV treatment to Phase IIIThe companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.
Three absurdly cheap dividend stocks that are trading at modest multiples of their expected earnings today are Merck ( MRK -0 ...
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
Progress has been made in HIV care. However, that doesn’t mean you don’t need a detailed plan for taking care of an ...
The national HIV prevalence was 16. 3% among adults aged 15 years and older, translating to an estimated 7. 4 million adults ...
From oral PrEP, to injectables, rings, and implants, this year's HIV Research for Prevention conference was all about options ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback